ClinicalTrials.gg
CompletedNCT02897856Updated Jul 24, 2019

Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures

A Phase 4 interventional study of Buccal midazolam and Intramuscular midazolam in Seizures, sponsored by Hamad Medical Corporation. Completed at 1 site in Qatar. Open to participants aged 6 Months to 14 Years. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
6 Months to 14 Years
Sex
All
01

Study summary

The goal of this study is to prove that intramuscular midazolam is more effective than buccal midazolam in cessation of seizure activity with comparable side effects.

Read the detailed description

Both buccal and intramuscular midazolam have been used to control seizures with variable succuss rates and side effects.

In this study the investigators are going to assign patient randomly to receive either buccal or intramuscular midazolam. Then will compare both efficacy and side effect in both groups.

02

Conditions studied

  • Seizures

Browse trials for

03

In context

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

This study's enrollment of 150 is above the median of 64 across 519 interventional studies indexed under Seizures.

Browse Seizures studies →

Lead sponsor

Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children 6 month to 14 years who will be presented to the pediatric emergency or attended by emergency medical service who have active seizure and had no intravenous access would be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • Cardiac arrest
  • Head trauma
  • Drowning
  • Congenital heart disease
  • Inborn errors of metabolism
  • Electrolyte imbalance (hypocalcaemia, hyponatremia and hypoglycemia)
  • Hemodynamic instability
  • Allergy to benzodiazepines
  • Focal seizures with preserved level of consciousness
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Active comparator
    Buccal midazolam

    Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg

    Drug: Buccal midazolam

  • Active comparator
    intramuscular midazolam

    Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.

    Drug: Intramuscular midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. Cessation of seizure activity five minutes after treatment with study medication.

    Cessation of abnormal motor activity with regaining of consciousness.

    Time frame: five minutes

Secondary outcomes

  1. Major side effects.

    Time frame: 2 hours after cessation of seizures.

  2. Duration of seizure.

    Time frame: 5 minutes

  3. Recurrence of seizure activity within one hour after treatment with study medication.

    Time frame: one hour

07

Study locations

1 site
  • Hamad medical corporation
    Doha, 3050, Qatar
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Nov 2018, 26 months.

Of 26 phase 4 interventional studies under Seizures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2016
First posted
Sep 13, 2016
StartActual
Sep 2016
Primary completionActual
Nov 2018
CompletionActual
Nov 2018
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02897856
Responsible party
DR. KHALID AL-ANSARI (Senior consultanat, Hamad Medical Corporation) — Principal investigator
First posted
Sep 13, 2016
Start date
Sep 2016
Primary completion
Nov 2018
Completion
Nov 2018
Last update
Jul 24, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midazolam

Start the discussion